Total Payments
$2,620
2024 Payments
$390.39
Companies
28
Transactions
75
Medicare Patients
2,982
Medicare Billing
$370,560
Payment Breakdown by Category
Food & Beverage$2,010 (76.7%)
Education$459.51 (17.5%)
Consulting$150.00 (5.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,010 | 68 | 76.7% |
| Education | $459.51 | 6 | 17.5% |
| Consulting Fee | $150.00 | 1 | 5.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $324.26 | 5 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $225.55 | 5 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $199.03 | 5 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $189.57 | 2 | $0 (2024) |
| Genentech USA, Inc. | $181.75 | 7 | $0 (2023) |
| GENZYME CORPORATION | $175.65 | 9 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $152.62 | 5 | $0 (2024) |
| Seattle Genetics, Inc. | $115.20 | 1 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $111.23 | 2 | $0 (2023) |
| Amgen Inc. | $103.79 | 5 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $390.39 | 12 | Janssen Scientific Affairs, LLC ($150.00) |
| 2023 | $843.84 | 29 | Astellas Pharma US Inc ($308.74) |
| 2022 | $552.99 | 20 | GENZYME CORPORATION ($101.51) |
| 2021 | $85.25 | 3 | Pharmacyclics LLC, An AbbVie Company ($56.95) |
| 2020 | $231.79 | 3 | Takeda Pharmaceuticals U.S.A., Inc. ($84.45) |
| 2019 | $292.45 | 4 | Seattle Genetics, Inc. ($115.20) |
| 2018 | $222.83 | 4 | SANOFI-AVENTIS U.S. LLC ($85.00) |
All Payment Transactions
75 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/28/2024 | Janssen Scientific Affairs, LLC | TALVEY (Biological) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: Oncology | ||||||
| 04/23/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: Oncology | ||||||
| 04/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $19.44 | General |
| 04/12/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: ONCOLOGY | ||||||
| 03/06/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $13.20 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 02/28/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $36.25 | General |
| Category: Oncology | ||||||
| 02/15/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $83.75 | General |
| 02/12/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $14.72 | General |
| Category: Oncology | ||||||
| 02/05/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.50 | General |
| Category: Hematology | ||||||
| 02/01/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA, TECVAYLI | Food and Beverage | In-kind items and services | $4.15 | General |
| Category: Oncology | ||||||
| 02/01/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA, TECVAYLI | Food and Beverage | In-kind items and services | $2.93 | General |
| Category: Oncology | ||||||
| 02/01/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA, TECVAYLI | Food and Beverage | In-kind items and services | $0.95 | General |
| Category: Oncology | ||||||
| 12/06/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2023 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $26.78 | General |
| Category: ONCOLOGY | ||||||
| 10/04/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $23.41 | General |
| Category: Hematology | ||||||
| 09/13/2023 | Genentech USA, Inc. | Alecensa (Biological), Gavreto, Rozlytrek | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: BioOncology | ||||||
| 08/30/2023 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: HORMONE THERAPY | ||||||
| 08/23/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $23.63 | General |
| Category: Hematology | ||||||
| 08/09/2023 | SOBI, INC | Doptelet (Drug) | Food and Beverage | In-kind items and services | $36.76 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 07/26/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: Oncology | ||||||
| 07/26/2023 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: BioOncology | ||||||
| 07/19/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $27.03 | General |
| Category: ONCOLOGY | ||||||
| 06/28/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $24.08 | General |
| Category: Oncology | ||||||
| 05/16/2023 | Genentech USA, Inc. | Gazyva (Biological), Venclexta | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: BioOncology | ||||||
| 05/11/2023 | Puma Biotechnology, Inc. | — | Food and Beverage | In-kind items and services | $18.04 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 806 | 1,251 | $189,160 | $95,649 |
| 2022 | 10 | 842 | 1,259 | $349,181 | $127,010 |
| 2021 | 9 | 763 | 1,276 | $207,355 | $92,251 |
| 2020 | 9 | 571 | 927 | $147,745 | $55,650 |
Total Patients
2,982
Total Services
4,713
Medicare Billing
$370,560
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 259 | 487 | $74,287 | $38,893 | 52.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 302 | 490 | $48,645 | $25,335 | 52.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 85 | 104 | $22,152 | $12,384 | 55.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 65 | 65 | $20,990 | $9,384 | 44.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 37 | 37 | $9,227 | $3,992 | 43.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 24 | 25 | $9,650 | $3,288 | 34.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 23 | 26 | $1,846 | $1,354 | 73.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 17 | $2,363 | $1,019 | 43.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 197 | 411 | $62,186 | $35,472 | 57.0% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2022 | 22 | 23 | $127,650 | $24,522 | 19.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 203 | 314 | $31,147 | $18,260 | 58.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 60 | 86 | $18,318 | $10,610 | 57.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 57 | 57 | $18,422 | $8,618 | 46.8% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2022 | 22 | 24 | $30,216 | $6,925 | 22.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 67 | 97 | $14,647 | $5,388 | 36.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 30 | 33 | $12,738 | $4,797 | 37.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 89 | 107 | $10,486 | $3,100 | 29.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 20 | 20 | $6,420 | $2,498 | 38.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $5,658 | $2,261 | 40.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 27 | $5,400 | $2,089 | 38.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 20 | 23 | $4,899 | $1,712 | 35.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 14 | 14 | $994.00 | $756.38 | 76.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 198 | 389 | $58,739 | $27,983 | 47.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 174 | 289 | $28,322 | $13,573 | 47.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 83 | 83 | $26,643 | $10,777 | 40.4% |
About Dr. Paul White, MD
Dr. Paul White, MD is a Hematology & Oncology healthcare provider based in Coeur D Alene, Idaho. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/03/2012. The National Provider Identifier (NPI) number assigned to this provider is 1356607485.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul White, MD has received a total of $2,620 in payments from pharmaceutical and medical device companies, with $390.39 received in 2024. These payments were reported across 75 transactions from 28 companies. The most common payment nature is "Food and Beverage" ($2,010).
As a Medicare-enrolled provider, White has provided services to 2,982 Medicare beneficiaries, totaling 4,713 services with total Medicare billing of $370,560. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Coeur D Alene, ID
- Active Since 04/03/2012
- Last Updated 07/25/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1356607485
Products in Payments
- TALVEY (Biological) $150.00
- IMBRUVICA (Drug) $116.63
- ADCETRIS (Biological) $115.20
- NINLARO (Drug) $111.23
- OPDIVO (Biological) $101.28
- SARCLISA (Biological) $97.35
- LYNPARZA (Drug) $86.49
- JEVTANA (Drug) $85.00
- ZEPZELCA (Drug) $81.43
- ELITEK (Biological) $78.30
- SOLIRIS (Drug) $72.84
- DARZALEX (Biological) $72.27
- Imbruvica (Drug) $69.99
- BLENREP (Biological) $66.14
- REBLOZYL (Biological) $61.54
- Xofigo (Drug) $52.32
- EPKINLY (Drug) $51.98
- Alecensa (Biological) $48.96
- Kyprolis (Drug) $47.52
- Lenvima (Drug) $36.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.